Aladay® MAX Ophthalmic Solution: Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 7 mg.
Aladay® MAX is a preparation of Olopatadine. Olopatadine is an anti-allergic compound which has been demonstrated to stabilize human conjunctival tissue mast cells, preventing the release of histamine and other inflammatory mediators. Olopatadine is a selective histamine H1-antagonist that inhibits Type I immediate hypersensitivity reactions. It has been shown to inhibit the release of pro-inflammatory mediators from human conjunctival mast and epithelial cells. Olopatadine has no significant effects on alpha-adrenergic, dopamine and muscarinic Type I and II receptors.
Aladay® MAX: Instill one drop in the affected eye(s) once daily.
No adequate and well controlled studies in pregnant women have been performed; it should be carefully considered whether the potential benefit to the mother justifies the potential risk to the embryo or foetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities of Olopatadine/metabolites in human breast milk. Olopatadine ophthalmic solution should be used with caution in breastfeeding woman.
Pediatric Use:
The safety and effectiveness of Aladay® MAX have been established in pediatric patients two years of age and older. Use of Aladay® MAX in these pediatric patients is supported by evidence from adequate and well-controlled studies of Aladay® MAX in adults and an adequate and well controlled study evaluating the safety of Aladay® MAX in pediatric and adult patients.
Not for injection or oral ingestion. For ophthalmic use only.
Keep away from light and store in a cool (4 to 25°C) and dry place. Keep out of reach of children. To prevent contamination of the dropper tip and solution, care should be taken. Don’t touch the eyelids, surrounding areas, finger or other surfaces with the dropper tip of the bottle. The bottle should be tightly closed when not in use. Do not use after 4 weeks of first opening.